28.90

3.92% -1.18

After Hours: 28.86 -0.04 -0.14%

Beam Therapeutics Inc (BEAM)

Overview News Price History Option Chain Financials Why BEAM Down? Discussions Forecast

Beam Therapeutics Inc stock is traded at $28.90, with a volume of 2.05M. It is down -3.92% in the last 24 hours and up +17.19% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Previous Close:

$30.08

Open:

$30.67

24h Volume:

2.05M

Relative Volume:

1.04

Market Cap:

$2.97B

Revenue:

$139.74M

Net Income/Loss:

$-79.99M

P/E Ratio:

-28.45

EPS:

-1.0157

Net Cash Flow:

$-360.05M

1W Performance:

-5.43%

1M Performance:

+17.19%

6M Performance:

+25.27%

1Y Performance:

+45.81%

1-Day Range:

$28.50

$31.24

1-Week Range:

$28.50

$31.93

52-Week Range:

$15.35

$36.44

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name

Beam Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

857-327-8775

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

511

Twitter

Next Earnings Date

2026-05-05

Latest SEC Filings

BEAM's Discussions on Twitter

Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BEAM Beam Therapeutics Inc	28.90	3.09B	139.74M	-79.99M	-360.05M	-1.0157
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-20-26	Initiated	Canaccord Genuity	Buy
Oct-09-25	Initiated	Jefferies	Buy
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Dec-08-23	Downgrade	Jefferies	Buy → Hold
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Dec-13-22	Initiated	Citigroup	Buy
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Apr-28-22	Initiated	Credit Suisse	Neutral
Jan-05-22	Initiated	Guggenheim	Buy
Oct-19-21	Initiated	SVB Leerink	Outperform
Sep-24-21	Resumed	Stifel	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight
Feb-16-21	Initiated	Wells Fargo	Overweight
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-21	Initiated	Stifel	Hold
Aug-05-20	Initiated	William Blair	Outperform
Mar-02-20	Initiated	Barclays	Overweight
Mar-02-20	Initiated	JP Morgan	Overweight
Mar-02-20	Initiated	Jefferies	Buy
Mar-02-20	Initiated	Wedbush	Outperform

View All

Beam Therapeutics Inc Stock (BEAM) Latest News

May 04, 2026

Why Beam Therapeutics (BEAM) Is Up 5.3% After TIME100 Spotlight and Vanguard Stake Disclosure - Yahoo Finance

May 04, 2026

Prime Editing and CRISPR Market is expected to Hit US$ 11.46 - openPR.com

May 04, 2026

May 03, 2026

Beam Therapeutics’ TIME Honor Puts Base Editing And Valuation In Focus - Yahoo Finance

May 03, 2026

May 02, 2026

Beam Therapeutics Advances Base Editing Platform with Strong Clinical Data - HarianBasis.co

May 02, 2026

Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now? - Insider Monkey

May 02, 2026

Apr 30, 2026

14 Stocks on Jim Cramer’s Radar: Nokia, Cameco, and AI Stocks’ Dip - Insider Monkey

Apr 30, 2026

Jim Cramer Believes Beam Therapeutics Is a “Speculative Situation” - Insider Monkey

Apr 30, 2026

Price-Driven Insight from (BEAM) for Rule-Based Strategy - Stock Traders Daily

Apr 30, 2026

MSN Money - MSN

Apr 30, 2026

Apr 29, 2026

Vanguard Capital Mgmt (NASDAQ: BEAM) reports 5.02% ownership stake - Stock Titan

Apr 29, 2026

H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo

Apr 29, 2026

Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study - Insider Monkey

Apr 29, 2026

Concurrent Investment Advisors LLC Invests $2.13 Million in Beam Therapeutics Inc. $BEAM - MarketBeat

Apr 29, 2026

Apr 28, 2026

10 Best Biotech Stocks with Highest Upside Potential - Insider Monkey

Apr 28, 2026

Beam Therapeutics (BEAM) Projected to Post Earnings on Tuesday - MarketBeat

Apr 28, 2026

Apr 27, 2026

Beam Therapeutics shows rising relative strength; still shy of key benchmark - MSN

Apr 27, 2026

Beam Therapeutics (NASDAQ:BEAM) Trading Up 8.4%What's Next? - MarketBeat

Apr 27, 2026

Beam Therapeutics (BEAM) Shares Surge 10.7% on Positive Market M - GuruFocus

Apr 27, 2026

S&P 500 Holds Near Highs Despite Oil Shock and Weak Breadth Data - Investing.com

Apr 27, 2026

Beam Therapeutics (BEAM) Shares Rise Over 10% Amid Positive Mark - GuruFocus

Apr 27, 2026

XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday - Benzinga

Apr 27, 2026

3 Biotech Stocks That Could Benefit from the Patent Cliff - MarketBeat

Apr 27, 2026

Beam Therapeutics (BEAM) H.C. Wainwright 27th Annual Global Investment Conference summary - Quartr

Apr 27, 2026

Beam Therapeutics (BEAM) Jefferies 2024 Global Healthcare Conference Summary - Quartr

Apr 27, 2026

Beam Therapeutics (BEAM) Jefferies London Healthcare Conference 2024 Summary - Quartr

Apr 27, 2026

Apr 26, 2026